Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hope Cottrill, MD, highlights practice-changing developments in endometrial cancer care, the benefits of local control with radiation in patients with locally aggressive disease, and questions that remain regarding treatment sequencing with immunotherapy.
Marijo Bilusic, MD, PhD, highlights key insights about renal cell carcinoma that were presented at the meeting covering considerations on sequencing TKIs, the need for further research to elucidate novel therapies, and the importance of offering clinical trials to all patients with genitourinary malignancies.
Jaime R. Merchán, MD, discusses the evolution and current role of IO/TKI regimens in advanced RCC; highlights data from the phase 3 CLEAR and KEYNOTE-426 trials supporting the use of pembrolizumab-based regimens in untreated ccRCC; and speculates on how future biomarker-driven research could improve the benefit seen with these combinations in this disease.
Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research.
Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.